🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

No one celebrates birthdays bigger and better than we do! Happy birthday to our very own Dr. Kaira Church 🥳🎊

Which are the highest cited original research publications in #PancreaticCancer over the past five years (from 2020 to 2024 end)? All metrics obtained from Google Scholar (caveat: GS tends to OVERESTIMATE citations but the trends are consistent overall). 🧵 Below:

We break from science only for snacks! Thanks to Casey for bringing a giant Kalluri Lab-sized Rosca de Reyes (King’s Cake) to share 💚 Navid and Riya will have good luck this year 🤞

It was our privilege to host Hidde Pleogh for his 1️⃣st visit to MD Anderson Cancer Center, and most importantly, his final stop before retirement‼️ This Smith Family Distinguished Lecture was one for the books!

📣Our latest review article is now online at ACS Nano ! “Natural and Bioengineered Extracellular Vesicles in Diagnosis, Monitoring and Treatment of Cancer” Read the full article here: pubs.acs.org/doi/10.1021/ac…

Pleased to share article ✌️this week! We show that allogenic and non-immunogenic exosomes can be engineered to induce specific immune responses, with therapeutic potential. Full article is online ACS Nano now! ⬇️ pubs.acs.org/doi/10.1021/ac…

New preprint by Kate McAndrews (previously Kalluri Lab, now PI at MD Anderson Cancer Center): CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in #PancreaticCancer In this preclinical study, Kate demonstrates that while acute

📣Our latest study is out this week in AJOGMFM. Amniotic fluid evRNA and cfRNA reveal fetal adaptations in twin-twin transfusion syndrome. Great to work with the awesome Jackie Parchem, MD and colleagues at UTHealth Houston OBGYN on this project. 🔗ajogmfm.org/article/S2589-…

Our most recent work provides strong rationale for combination of KRAS inhibitors & anti-CTLA4 in clinical trials. biorxiv.org/content/10.110… KRASi synergize with anti-CTLA4 to prevent resistance by epigenetic reprogramming of Tregs & TLS recruitment. Anirban Maitra Kalluri Lab

KRASG12D-Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients medrxiv.org/content/10.110… First in human personalized medicine with exosomes! Kalluri Lab Anirban Maitra

Raghu delivers the keynote address at #VESICON2025 and is recognized as the Guest of Honor. Great to share our latest work in EVs, and thanks to Indian Extracellular Vesicles Society- IEVS and Mahindra University for hosting!

ICYMI an interesting preprint from Kalluri Lab MD Anderson Cancer Center that addresses the pivotal question of targeting the correct immune checkpoint in combination with KRAS inhibition in #PancreaticCancer. Hint: it may not be aPD-1! And why blocking CTLA4 may have greater efficacy.

A true “farm to table” effort at MD Anderson Cancer Center funded by our #PancreaticCancer Moonshot. The 1st clinical trial of systemic exosomes targeting mutant KRAS in metastatic pancreatic cancer. Five years from Raghu Kalluri discovery to patients. No DLTs whatsoever to speak of.

Results from Phase I trial of iExosomes coming to you live from AACR! 🗓️April 29 ⏰3:20 PM CT Kalluri Lab discovery ➡️ patients in only 5 years. Join us in person or online!

🤩🤩🤩

Congrats to KL postdoc Miguel Pereira-Silva, PharmD | PhD, PG on receiving an EDA Julia Polak Award from the European Society for Biomaterials! 🎉🎉🎉 Miguel is a talented scientist and highly deserving of this recognition. We are so proud!

Yesterday we celebrated Xin’s graduation from the Bioengineering PhD program Rice University. 🎓🦉 Congratulations Dr. Luo! 🎉🎉🎉